Human Papillomavirus Vaccine Intention Among College Men: What's Oral Sex Got to Do With It?
ABSTRACT To identify associations between engaging in oral sex and perceived risk of oral cancer among college men. Also, to identify associations, and their moderating factors, between oral sex and human papillomavirus (HPV) vaccine acceptance.
Young men were recruited from 2 university campuses in the South (N = 150). Men completed an audio computer-assisted self-administered interview.
With the exception of receiving fellatio, each measure of oral sex behavior was significantly associated with greater perceived risk of oral cancer. Four oral sex behaviors evidenced significant associations with vaccine acceptance. Men engaging in recent oral sex or reporting oral sex behaviors with more than 2 partners were more likely to indicate vaccine intent. African American/black race, communication with parents about sex-related topics, and HPV-related stigma/shame were identified as moderating factors.
Young college men giving or receiving oral sex with multiple partners may be predisposed to HPV vaccination.
- [Show abstract] [Hide abstract]
ABSTRACT: Head and neck squamous cell carcinoma (HNSCC) is an aggressive epithelial malignancy. It is known to be the most common neoplasm appearing in the upper aerodigestive tract. The poor 5‑year survival rate has remained unchanged in the last decades even though improved techniques in surgery, radiation and chemotherapy have been established. In contrast to the overall decreasing incidence of head and neck cancer in the US, the incidence of HPV-associated oropharyngeal cancer is increasing, indicating the importance of viral etiology. Furthermore, growth and invasion of HNSCC are strongly influenced by the extracellular matrix (ECM). Matrix metalloproteinases (MMP) have been shown to play key roles in the remodeling of the ECM. Imatinib (STI 571) was originally designed to inhibit the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. But it also has an inhibitory impact, e.g., on the protein-tyrosine-kinase (PTK) receptor c-kit and on its PTK activity in HNSCC. In this study, we incubated the HNSCC cell lines HNSCC 11A and 14C and the p16-positive SCC line CERV196 with increasing concentrations of imatinib or carboplatin. After an incubation time of up to 10 days, we evaluated MMP-2 and -14 expression by ELISA techniques and immunohistochemistry. MMP-2 and -14 expression was demonstrated in all incubated tumor cell lines. Especially incubation with imatinib resulted in a significant decrease in MMP expression in incubated cell lines. Our results indicate that the expression of MMP-2 and -14 is suppressed in the presence of imatinib. Thus, imatinib may exert in part its inhibitory effect on malignant cell growth via the blockage of the signal transduction of PTK receptors. Further studies are warranted, especially keeping in mind the moderate toxicity of imatinib.Oncology Reports 07/2012; 28(1):172-8. DOI:10.3892/or.2012.1766 · 2.19 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Objective: To examine HPV vaccination rates including initiation and completion of the vaccine series, and barriers to vaccination in a sample of male college students. Participants: Male students between the ages of 18 and 25 who reported being currently or previously sexually active (N = 735). Methods: A cross-sectional web-based survey was administered during October 2012 at a large public university in the northeast United States. Student email addresses were obtained from the university after Institutional Review Board approval. Results: Although condom use was low and number of lifetime sexual partners was high, 93% reported they were not at risk for sexually transmitted infections. The college men in the sample had low HPV vaccine awareness, knowledge, perceived severity, and perceived susceptibility, and 74% of the sample had not obtained the HPV vaccine. Conclusions: There is a disconnect between actual and perceived risks of HPV and barriers to HPV vaccination exist.Journal of American College Health 12/2013; DOI:10.1080/07448481.2013.872649 · 1.45 Impact Factor